Knockout mice suggest opposing effects on lysosomal enzymes and neurodegeneration in frontotemporal dementia, implicating an ATPase.
Analysis of brain tissue from Alzheimer’s patients offers a glimpse of proteomic changes in the disease.
Researchers identified nuclear protein SRSF1 as the culprit that allows aberrant C9ORF72 RNA to escape into cytoplasm and give rise to toxic dipeptide repeat proteins.
Tau takes its place among the growing cadre of neurodegenerative disease proteins known to form liquid droplets. How the protein’s liquid form relates to its toxicity remains unclear.
Transcriptional profiling of human microglia sheds light on species differences, raising caution about translatability of rodent studies.
At a conference in Heidelberg, researchers proposed that Aβ oligomers trigger local translation of tau in cytosol and dendrites, and that targeting this aberrant tau may preserve synapses.
An antibody that activates Notch 3 signaling helps keep retinal blood vessels intact in a mouse model of the small vessel disease CADASIL.
A new prize seeks the ideal mix of factors to forecast who will progress to Alzheimer’s symptoms.
Genetics isn’t just for geneticists anymore. With the rise of direct-to-consumer genetic testing companies like 23andMe, anyone can riffle through their genotypes at hundreds of thousands of positions across their genome. These include dozens of autosomal-dominant mutations for Alzheimer’s and other neurodegenerative diseases, as well as many risk alleles. Much of the data shared with customers has not been validated. Some researchers question the ethics of this data dump, while some see it as an opportunity to usher carriers of pathogenic mutations toward prevention trials.
- Benjamin Wolozin on Tau Hooks Up with RNA to Form Droplets
- Shane Liddelow on Human and Mouse Microglia Look Alike, but Age Differently
- Joseph Arboleda-Velasquez on Immunotherapy for Cerebral Small Vessel Disease?
- Gabrielle Leblanc on Immunotherapy for Cerebral Small Vessel Disease?
- Elena Galea on For Better and Worse, TDP-43 Controls Microglia’s Phagocytic Prowess
- Axel Montagne, Zhen Zhao and Berislav Zlokovic on Immunotherapy for Cerebral Small Vessel Disease?
- Walter Kukull on New Study Disputes Claim That Heartburn Meds Raise Dementia Risk
- Gael Nicolas and Anne Rovelet-Lecrux on Novel presenilin mutations within Moroccan patients with Early-Onset Alzheimer's Disease.
- Matteo Santoro and Gernot Riedel on Trigger Warning: α-Synuclein Sets Off T Cells in Parkinson’s
- Markus Zweckstetter on Tau Filaments from the Alzheimer’s Brain Revealed at Atomic Resolution
- Eckhard Mandelkow on Tau Filaments from the Alzheimer’s Brain Revealed at Atomic Resolution
- David Sanders on Tau Filaments from the Alzheimer’s Brain Revealed at Atomic Resolution
- Carol Brayne and Suvi Hokkanen on For Better and Worse, TDP-43 Controls Microglia’s Phagocytic Prowess
- Christos Proukakis on Could Genetic Mosaicism in Adult Neurons Precipitate Disease?
- Richard Caselli on APOE4 Subtly Alters Brain Network Activity With Age
- Amy Borenstein on Preventing Dementia: Getting Closer to Recommendations
- Steffen Rossner on New Alzheimer’s Drug Shows Safety, Hints of Efficacy in Phase 2
- Mychael Lourenco on Loss of Tau Function Triggers Insulin Resistance in the Brain
- Michael Zasloff on Put ’Em Up: Does α-Synuclein Help Fight Microbes in the Gut?
- John Woulfe on Put ’Em Up: Does α-Synuclein Help Fight Microbes in the Gut?
- Stephen Gomperts on Risk Score Forecasts Cognitive Decline in Parkinson’s